SEP 08, 2020 9:00 AM PDT

Advancing Toward Personalized Medicine in Lung Cancer: A Focus on Gene Rearrangement Testing

Speaker
  • Global Scientific Affairs Manager at Abbott Molecular
    Biography
      Yelina Noskina, Ph.D. received her doctoral degree from Rush University in Chicago, she joined Abbott Molecular, after her post-doctoral work at Northwestern University and the University of Illinois, Chicago. She has been with Abbott for over 15 years, the majority of that time has been spent focusing on Oncology at Abbott Molecular, with roles that ranged from assay support, to laboratory operations, and training. In her current role as Global Scientific Affairs Manager focusing on oncology and companion diagnostics, Yelina has been working with healthcare professionals in the research and clinical molecular diagnostic fields with the end goal of bringing about the best testing and treatment options for oncology patients.

    Abstract
    Date:  September 8, 2020
    Time: 8:00am PDT,  11:00am EDT
     
    Advances in genomics and molecular biomarker testing have led to tremendous improvements, ushering in a new era of personalized medicine especially in the oncology practice. Many of these biomarkers have been identified as receptor tyrosine kinases, shown to be involved in the signaling pathways associated with tumor growth and development. More interesting is that a subset of the genetic alterations observed in these biomarkers are gene rearrangements that result in constitutively activated tyrosine kinases, thus providing targets for therapies that could effectively inhibit the tyrosine kinase activity. Non-small cell lung cancer patients have benefited considerably, from these advances in targeted therapies, as there are already several therapeutics to which patients positive for specific gene rearrangements have shown remarkable response. Identifying such rearrangements is becoming part of the preliminary standard of care when diagnosing non-small cell lung cancer. Various diagnostic assays have been developed to provide such information. This webinar will review the available molecular methodologies for identifying gene rearrangements specifically focusing on ALK and ROS1 gene rearrangement testing in non-small cell lung cancer. Included in the review will be an overview of the technology, the current recommendations, common practices and challenges associated with these methodologies, to better understand the available options in order to choose the best course of action throughout the patient treatment cycle.
     
    Learning Objectives
    • Review functionality of gene rearrangements
    • Overview of various methodologies for identifying gene rearrangements
    • Review of the guidelines, recommendations, common practices and difficulties associated with gene rearrangement testing
    • Considerations for the best course of action throughout the patient treatment cycle
     
     
    Webinars will be available for unlimited on-demand viewing after live event.
     
    LabRoots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this webinar, you can earn 1 Continuing Education credit once you have viewed the webinar in its entirety.

    Show Resources
    You May Also Like
    OCT 08, 2020 7:00 AM PDT
    C.E. CREDITS
    OCT 08, 2020 7:00 AM PDT
    DATE: October 8, 2020 TIME: 7:00am PDT, 10:00am EDT, 4:00pm CEST How often do you pipette in your cell culture lab every day? Usually, we do it so often that we tend stop thinking about ho...
    DEC 02, 2020 8:00 AM PST
    C.E. CREDITS
    DEC 02, 2020 8:00 AM PST
    DATE: December 2nd, 2020 TIME: 08:00am PDT, 11:00pm EDT Bioreactors and shakers are used to cultivate microorganisms, plant, insect, and mammalian cells in different volumes. Upscaling of pr...
    AUG 25, 2020 8:00 AM PDT
    C.E. CREDITS
    AUG 25, 2020 8:00 AM PDT
    DATE: August 25, 2020 TIME: 8:00am PDT, 10:00am CDT, 11:00am EDT Recombinant lentivirus (LV) and adeno-associated virus (AAV) are critical components of cell and gene therapies, which show g...
    SEP 10, 2020 9:00 AM PDT
    C.E. CREDITS
    SEP 10, 2020 9:00 AM PDT
    Date: September 10, 2020 Time: 9:00am (PDT), 12:00pm (EDT) Osmolality testing is relevant throughout the entire bioprocessing workflow. As customers look to refine mAb and gene therapy workf...
    JUN 23, 2020 10:00 AM PDT
    C.E. CREDITS
    JUN 23, 2020 10:00 AM PDT
    DATE: June 23, 2020 TIME: 10:00am PT Human mesenchymal stromal or stem cells (MSCs)-based immunomodulation treatment has been proposed as a suitable therapeutic approach for many diseases, s...
    NOV 16, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 16, 2020 8:00 AM PST
    Date: November 16, 2020 Time: 8:00am (PST), 11:00am (EST) CRISPR screening has become the prime discovery tool in modern biomedical research and drug discovery. At the same time, most screen...
    Loading Comments...
    Show Resources
    Attendees
    • See more